Efficacy of Spironolactone as Adjunctive Therapy to Sodium Valproate in Bipolar-I Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

The double-blind, randomized, placebo-controlled clinical trial involving 60 patients with bipolar disorder type 1 investigated the efficacy of spironolactone as an adjunctive therapy to sodium valproate. The study found that spironolactone significantly improved cognitive performance by the eighth week of the trial compared to the placebo group. However, there were no significant differences between the two groups in terms of manic symptoms, appetite, or body mass index. The study also found that spironolactone improved sleep quality by the fourth week, but this effect was not seen in the eighth week. The authors suggest further studies with larger sample sizes and longer durations to better understand the potential benefits of spironolactone in treating manic episodes of bipolar disorder.